NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis $1.97 +0.05 (+2.60%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.91▼$1.9850-Day Range$1.62▼$2.3652-Week Range$1.58▼$23.72Volume808,997 shsAverage Volume2.39 million shsMarket Capitalization$133.98 millionP/E RatioN/ADividend YieldN/APrice Target$17.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Amylyx Pharmaceuticals alerts: Email Address Amylyx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside793.4% Upside$17.60 Price TargetShort InterestHealthy8.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.06Based on 3 Articles This WeekInsider TradingSelling Shares$19,655 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.36) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.48 out of 5 starsMedical Sector299th out of 936 stocksPharmaceutical Preparations Industry138th out of 436 stocks 3.1 Analyst's Opinion Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAmylyx Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted8.22% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently decreased by 17.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMLX. Previous Next 2.3 News and Social Media Coverage News SentimentAmylyx Pharmaceuticals has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Amylyx Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 11 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have sold 278.13% more of their company's stock than they have bought. Specifically, they have bought $5,198.00 in company stock and sold $19,655.00 in company stock.Percentage Held by Insiders11.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($1.36) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amylyx Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More AMLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMLX Stock News HeadlinesJuly 18, 2024 | prnewswire.comKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmJuly 10, 2024 | benzinga.comWhy Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?July 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.June 21, 2024 | reuters.comAmylyx to buy bankrupt Eiger's experimental drug to treat low blood sugarJune 4, 2024 | businesswire.comAmylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 13, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Amylyx Pharmaceuticals on Positive ALS and Wolfram Syndrome TrialsMay 10, 2024 | markets.businessinsider.comBreaking Down Amylyx Pharma: 9 Analysts Share Their ViewsJuly 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.May 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Reports Q1 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 8, 2024 | businesswire.comAmylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care ConferenceMay 2, 2024 | businesswire.comAmylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024April 17, 2024 | msn.comAmylyx Pharmaceuticals (AMLX) Price Target Decreased by 17.36% to 4.34April 12, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial ResultsApril 11, 2024 | markets.businessinsider.comHold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market ProspectsApril 10, 2024 | msn.comAmylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited DisorderSee More Headlines Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMLX CUSIPN/A CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees384Year FoundedN/APrice Target and Rating Average Stock Price Target$17.60 High Stock Price Target$37.00 Low Stock Price Target$3.00 Potential Upside/Downside+793.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$49.27 million Net Margins-17.86% Pretax Margin-16.50% Return on Equity4.14% Return on Assets3.49% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio4.48 Sales & Book Value Annual Sales$380.79 million Price / Sales0.35 Cash Flow$0.61 per share Price / Cash Flow3.21 Book Value$6.42 per share Price / Book0.31Miscellaneous Outstanding Shares68,010,000Free Float60,049,000Market Cap$133.98 million OptionableOptionable Beta-0.64 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Joshua B. Cohen (Age 32)Co-Founder, Co-CEO & Director Comp: $1.08MMr. Justin B. Klee (Age 33)Co-Founder, Co-CEO & Director Comp: $1.08MMr. James M. Frates M.B.A. (Age 57)Chief Financial Officer Comp: $763.16kMs. Gina M. Mazzariello (Age 53)Chief Legal Officer & General Counsel Comp: $689.26kDr. Camille L. Bedrosian M.D. (Age 71)Chief Medical Officer Comp: $232.6kMr. Tom HolmesChief Technical Operations OfficerLindsey AllenHead of Investor Relations & CommunicationsMs. Shauna HorvathHead of Global MarketingMs. Linda A. ArsenaultChief Human Resources OfficerMr. Chris AielloHead of Canada & GMMore ExecutivesKey CompetitorsTerns PharmaceuticalsNASDAQ:TERNNeurogeneNASDAQ:NGNEMereo BioPharma GroupNASDAQ:MREOPepGenNASDAQ:PEPGPureTech HealthNASDAQ:PRTCView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 13,509 shares on 7/26/2024Ownership: 0.042%Hennion & Walsh Asset Management Inc.Bought 6,116 shares on 7/20/2024Ownership: 0.175%SG Americas Securities LLCBought 29,697 shares on 7/12/2024Ownership: 0.082%CWM LLCBought 14,613 shares on 7/10/2024Ownership: 0.042%Farallon Capital Management LLCBought 1,150,221 shares on 5/24/2024Ownership: 1.691%View All Insider TransactionsView All Institutional Transactions AMLX Stock Analysis - Frequently Asked Questions How have AMLX shares performed this year? Amylyx Pharmaceuticals' stock was trading at $14.72 at the beginning of the year. Since then, AMLX shares have decreased by 86.6% and is now trading at $1.97. View the best growth stocks for 2024 here. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced its earnings results on Friday, May, 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of $0.24 by $0.70. The business had revenue of $88.64 million for the quarter, compared to the consensus estimate of $113.26 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a positive trailing twelve-month return on equity of 4.14%. When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Top institutional investors of Amylyx Pharmaceuticals include Hennion & Walsh Asset Management Inc. (0.17%), SG Americas Securities LLC (0.08%), Allspring Global Investments Holdings LLC (0.04%) and CWM LLC (0.04%). Insiders that own company stock include Morningside Venture Investment, Joshua B Cohen, Justin B Klee, Global Investors Lp Viking, George M Milne Jr, Patrick D Yeramian, Gina Mazzariello and Daphne Quimi. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMLX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
